PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPregabalin
Lyrica(pregabalin)
Lyrica, Pregabalin (pregabalin) is a small molecule pharmaceutical. Pregabalin was first approved as Lyrica on 2004-07-05. It is used to treat fibromyalgia, postherpetic neuralgia, seizures, and spinal cord injuries in the USA. It has been approved in Europe to treat anxiety disorders, epilepsy, and neuralgia.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
wounds and injuriesD014947
mental disordersD001523
Trade Name
FDA
EMA
Lyrica, Pregabalin (discontinued: Pregabalin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pregabalin
Tradename
Company
Number
Date
Products
LYRICAUpjohnN-021446 RX2004-12-30
8 products, RLD, RS
LYRICAUpjohnN-022488 RX2010-01-04
1 products, RLD, RS
LYRICA CRUpjohnN-209501 RX2017-10-11
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lyricaNew Drug Application2023-12-20
lyrica crNew Drug Application2024-03-19
pregabalinANDA2024-10-29
pregabalin capsules, cvANDA2022-03-16
pregabalin extended releaseANDA2022-09-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
spinal cord injuriesEFO_1001919D013119—
postherpetic neuralgia—D051474—
fibromyalgiaEFO_0005687D005356M79.1
seizuresHP_0002069D012640G40.4
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pregabalin, Lyrica Cr, Upjohn
89456202026-11-02DPU-2136, U-2137
91445592026-11-02DP
100224472026-11-02U-2136, U-2137
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02B: Other analgesics and antipyretics in atc
— N02BF: Gabapentinoids, analgesics and antipyretics
— N02BF02: Pregabalin
HCPCS
No data
Clinical
Clinical Trials
569 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeuralgiaD009437EFO_0009430—722332431116
Postoperative painD010149—G89.1841120281975
Diabetic neuropathiesD003929EFO_1000783—2251915461
PainD010146EFO_0003843R523181991560
FibromyalgiaD005356EFO_0005687M79.1241981950
Myofascial pain syndromesD009209EFO_1001054—241961948
Peripheral nervous system diseasesD010523HP_0009830G641141910343
Healthy volunteers/patients———31——3135
EpilepsyD004827EFO_0000474G40.9121310732
SeizuresD012640HP_0002069G40.412186127
Show 115 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50—43—18
HerniaD006547HP_0100790K40-K46——2—24
Hiv infectionsD015658EFO_0000764B20——3——3
Sleep wake disordersD012893—G471—1—13
DementiaD003704EFO_0003862F03—12——2
Kidney calculiD007669EFO_0004253N20—12——2
Urologic diseasesD014570—N39.9——1—12
Bone fracturesD050723EFO_0003931T14.81—1——2
Spinal fusionD013123————1—12
PancreatitisD010195HP_0001733K85—11—12
Show 35 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NauseaD009325HP_0002018R11.0—2——13
Small fiber neuropathyD000071075——11——13
Alcohol drinkingD000428EFO_0004329——2———2
MucositisD052016EFO_1001898——1——12
Conscious sedationD016292———1——12
MyalgiaD063806HP_0003326M79.1—1——12
ComplianceD003187———1———1
LymphomaD008223—C85.9—1———1
CataractD002386HP_0000518H26.9—1———1
Dental pinsD003772———1———1
Show 20 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple fracturesD000069076HP_0002757—1————1
MalnutritionD044342EFO_0008572E40-E461————1
Marijuana abuseD002189EFO_0007191F121————1
Refractive errorsD012030EFO_0003908H52.71————1
Tobacco use disorderD014029—F171————1
NeuritisD009443——1————1
ParasomniasD020447—G47.51————1
Pain thresholdD017288——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ganglion cystsD045888—M67.4————22
Systemic sclerodermaD012595EFO_0000717M34.0————11
Localized sclerodermaD012594EFO_1001361L94.0————11
Diffuse sclerodermaD045743EFO_0000404—————11
ArthroplastyD001178——————11
Gynecologic surgical proceduresD013509——————11
Financial stressD000086522——————11
Coronary artery diseaseD003324—I25.1————11
Coronary stenosisD023921EFO_1000882—————11
Ankle fracturesD064386—S82.5————11
Show 39 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePregabalin
INNpregabalin
Description
Pregabalin is a gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). It binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. It has a role as an anticonvulsant and a calcium channel blocker. It derives from a gamma-aminobutyric acid. Pregabalin is a 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.
Classification
Small molecule
Drug classgabamimetics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)C[C@H](CN)CC(=O)O
Identifiers
PDB—
CAS-ID148553-50-8
RxCUI—
ChEMBL IDCHEMBL1059
ChEBI ID64356
PubChem CID5486971
DrugBankDB00230
UNII ID55JG375S6M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Lyrica – Viatris
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lyrica – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Pregabalin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 17,788 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
159,129 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use